- Home
- BIAF vs BLRX Comparison
BIAF vs BLRX Comparison
Compare BIAF & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- BLRX
- Stock Information
- Founded
- BIAF 2014
- BLRX 2003
- Country
- BIAF United States
- BLRX Israel
- Employees
- BIAF N/A
- BLRX N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- BLRX Health Care
- Exchange
- BIAF Nasdaq
- BLRX Nasdaq
- Market Cap
- BIAF 12.2M
- BLRX 12.2M
- IPO Year
- BIAF 2022
- BLRX 2011
- Fundamental
- Price
- BIAF $0.75
- BLRX $2.99
- Analyst Decision
- BIAF Hold
- BLRX Buy
- Analyst Count
- BIAF 1
- BLRX 2
- Target Price
- BIAF N/A
- BLRX $26.00
- AVG Volume (30 Days)
- BIAF 28.2M
- BLRX 26.4K
- Earning Date
- BIAF 05-14-2025
- BLRX 05-27-2025
- Dividend Yield
- BIAF N/A
- BLRX N/A
- EPS Growth
- BIAF N/A
- BLRX N/A
- EPS
- BIAF N/A
- BLRX N/A
- Revenue
- BIAF $9,362,022.00
- BLRX $28,940,000.00
- Revenue This Year
- BIAF $25.19
- BLRX N/A
- Revenue Next Year
- BIAF $20.00
- BLRX N/A
- P/E Ratio
- BIAF N/A
- BLRX N/A
- Revenue Growth
- BIAF 269.68
- BLRX 502.92
- 52 Week Low
- BIAF $0.24
- BLRX $2.85
- 52 Week High
- BIAF $3.16
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- BIAF 60.32
- BLRX 38.75
- Support Level
- BIAF $0.24
- BLRX $3.01
- Resistance Level
- BIAF $1.55
- BLRX $3.61
- Average True Range (ATR)
- BIAF 0.13
- BLRX 0.21
- MACD
- BIAF 0.08
- BLRX 0.02
- Stochastic Oscillator
- BIAF 38.64
- BLRX 17.11
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.